首页> 外文期刊>Chemistry: A European journal >Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling
【24h】

Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling

机译:损害RAS致癌信号传导的核苷酸交换抑制剂的研制

获取原文
获取原文并翻译 | 示例
           

摘要

Despite more than three decades of intense effort, no anti-Ras therapies have reached clinical application. Contributing to this failure has been an underestimation of Ras complexity and a dearth of structural information. In this regard, recent studies have revealed the highly dynamic character of the Ras surface and the existence of transient pockets suitable for small-molecule binding, opening up new possibilities for the development of Ras modulators. Herein, a novel Ras inhibitor (compound 12) is described that selectively impairs mutated Ras activity in a reversible manner without significantly affecting wild-type Ras, reduces the Ras-guanosine triphosphate (GTP) levels, inhibits the activation of the mitogen-activated protein kinase (MAPK) pathway, and exhibits remarkable cytotoxic activity in Rasdriven cellular models. The use of molecular dynamics simulations and NMR spectroscopy experiments has enabled the molecular bases responsible for the interactions between compound 12 and Ras protein to be explored. The new Ras inhibitor binds partially to the GTP-binding region and extends into the adjacent hydrophobic pocket delimited by switch II. Hence, Ras inhibitor 12 could represent a new compound for the development of more efficacious drugs to target Ras-driven cancers; a currently unmet clinical need.
机译:尽管三十年的强烈努力,但没有抗RAS疗法达到临床应用。对这种失败的贡献是低估了RAS复杂性和结构信息的缺乏。在这方面,最近的研究揭示了RAS表面的高动态特性和适合于小分子结合的瞬态口袋的存在,开辟了RAS调节剂的开发的新可能性。在此,描述了一种新的RAS抑制剂(化合物12),其中选择性地损害突变的RAS活性以可逆的方式,而不会显着影响野生型RA,减少了促毒素 - 鸟苷(GTP)水平,抑制了丝裂原活化蛋白的激活激酶(MAPK)途径,并在Rasdriven蜂窝模型中表现出显着的细胞毒性活性。分子动力学模拟和NMR光谱实验的使用使得负责化合物12和Ras蛋白之间的相互作用的分子碱能够被探索。新的RAS抑制剂部分地与GTP结合区域结合,并延伸到通过开关II限定的相邻疏水袋中。因此,RAS抑制剂12可以代表一种新化合物,用于靶向RAS驱动的癌症更有效的药物;目前未满足的临床需求。

著录项

  • 来源
    《Chemistry: A European journal》 |2017年第7期|共10页
  • 作者单位

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    Universitat Autònoma de Barcelona 08193 Bellaterra Barcelona (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    CIC bioGUNE Parque Tecnoljgico de Bizkaia Edif. 801A 48160 Derio (Spain);

    Department of Cellular and Molecular Medicine Centro de Investigaciones Biológicas CSIC 28040 Madrid (Spain);

    Department of Cellular and Molecular Medicine Centro de Investigaciones Biológicas CSIC 28040 Madrid (Spain);

    Universitat Autònoma de Barcelona 08193 Bellaterra Barcelona (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

    Instituto de Química Orgánica General IQOG-CSIC Juan de la Cierva 3 28006 Madrid (Spain);

    Departamento de Química Orgánica I Facultad de Ciencias Químicas Universidad Complutense de Madrid 28040 Madrid (Spain);

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 应用化学;
  • 关键词

    cancer; drug design; inhibitors; medicinal chemistry; proteins;

    机译:癌症;药物设计;抑制剂;药物化学;蛋白质;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号